| Q36602170 | Activated FXR Inhibits Leptin Signaling and Counteracts Tumor-promoting Activities of Cancer-Associated Fibroblasts in Breast Malignancy |
| Q33934005 | Anti-proliferative effect of LXR agonist T0901317 in ovarian carcinoma cells |
| Q38059807 | Anticancer steroids: linking natural and semi-synthetic compounds |
| Q39202139 | Bile acids affect the growth of human cholangiocarcinoma via NF-kB pathway |
| Q36945630 | Cardiomyocyte-expressed farnesoid-X-receptor is a novel apoptosis mediator and contributes to myocardial ischaemia/reperfusion injury |
| Q38648804 | Clinical significance of farnesoid X receptor expression in thyroid neoplasia. |
| Q57044787 | Consumption of Mediterranean versus Western Diet Leads to Distinct Mammary Gland Microbiome Populations |
| Q34626518 | Deciphering the nuclear bile acid receptor FXR paradigm |
| Q90862879 | Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome |
| Q37131369 | Deoxycholate promotes survival of breast cancer cells by reducing the level of pro-apoptotic ceramide |
| Q91584954 | Differences in the early stage gene expression profiles of lung adenocarcinoma and lung squamous cell carcinoma |
| Q39860554 | Differential modulation of farnesoid X receptor signaling pathway by the thiazolidinediones |
| Q50753027 | Direct effect of chenodeoxycholic acid on differentiation of mouse embryonic stem cells cultured under feeder-free culture conditions. |
| Q57462893 | Effects of farnesoid-X-receptor SUMOylation mutation on myocardial ischemia/reperfusion injury in mice |
| Q44968916 | Enhanced expression of farnesoid X receptor in human hepatocellular carcinoma |
| Q90640205 | Enteric Microbiota⁻Gut⁻Brain Axis from the Perspective of Nuclear Receptors |
| Q61813678 | Expression of NR1H3 in endometrial carcinoma and its effect on the proliferation of Ishikawa cells in vitro |
| Q53284274 | Expression of the nuclear bile acid receptor/farnesoid X receptor is reduced in human colon carcinoma compared to nonneoplastic mucosa independent from site and may be associated with adverse prognosis. |
| Q37376356 | FXR agonists enhance the sensitivity of biliary tract cancer cells to cisplatin via SHP dependent inhibition of Bcl-xL expression |
| Q37282312 | FXR: a metabolic regulator and cell protector |
| Q38115716 | Farnesoid X receptor alpha: a molecular link between bile acids and steroid signaling? |
| Q37192731 | Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development |
| Q33828171 | Farnesoid X receptor deletion improves cardiac function, structure and remodeling following myocardial infarction in mice |
| Q35786712 | Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression |
| Q37448273 | Farnesoid X receptor ligand CDCA suppresses human prostate cancer cells growth by inhibiting lipid metabolism via targeting sterol response element binding protein 1. |
| Q39534958 | Farnesoid X receptor protects human and murine gastric epithelial cells against inflammation-induced damage |
| Q33642712 | Farnesoid X receptor protects liver cells from apoptosis induced by serum deprivation in vitro and fasting in vivo |
| Q34727267 | Farnesoid X receptor, overexpressed in pancreatic cancer with lymph node metastasis promotes cell migration and invasion |
| Q28571177 | Farnesoid X receptor, through the binding with steroidogenic factor 1-responsive element, inhibits aromatase expression in tumor Leydig cells |
| Q47144864 | Gene Expression Profiling Reveals Novel Candidate Markers of Ovarian Carcinoma Intraperitoneal Metastasis. |
| Q37346998 | Guggulsterone inhibits tumor cell proliferation, induces S-phase arrest, and promotes apoptosis through activation of c-Jun N-terminal kinase, suppression of Akt pathway, and downregulation of antiapoptotic gene products. |
| Q28303272 | Hormone response element binding proteins: novel regulators of vitamin D and estrogen signaling |
| Q38937273 | Impact of bile acids on the growth of human cholangiocarcinoma via FXR. |
| Q47302008 | Increased levels of the novel hepatokine fetuin B in patients with intrahepatic cholestasis of pregnancy |
| Q54473491 | Inhibition of Leydig tumor growth by farnesoid X receptor activation: the in vitro and in vivo basis for a novel therapeutic strategy. |
| Q36704205 | Inhibition of farnesoid X receptor controls esophageal cancer cell growth in vitro and in nude mouse xenografts |
| Q26764743 | Lipid-sensors, enigmatic-orphan and orphan nuclear receptors as therapeutic targets in breast-cancer |
| Q39260482 | Mechanistic examination of walnuts in prevention of breast cancer |
| Q41412793 | MicroRNA-92 promotes gastric cancer cell proliferation and invasion through targeting FXR. |
| Q65001698 | Microbiome-Microbial Metabolome-Cancer Cell Interactions in Breast Cancer-Familiar, but Unexplored. |
| Q33579464 | Minireview: Nuclear receptor-controlled steroid hormone synthesis and metabolism |
| Q24655100 | Molecular mechanisms involved in farnesol-induced apoptosis |
| Q59807976 | Natural Products to Fight Cancer: A Focus on Juglans regia |
| Q47153848 | NcRNAs and Cholangiocarcinoma |
| Q33705070 | Nuclear receptor SHP, a death receptor that targets mitochondria, induces apoptosis and inhibits tumor growth. |
| Q38161329 | Nuclear receptor small heterodimer partner in apoptosis signaling and liver cancer |
| Q36683880 | Nuclear receptors and the Warburg effect in cancer |
| Q37725708 | Orphan nuclear receptors as targets for drug development |
| Q36907762 | Pan-cancer analyses of the nuclear receptor superfamily |
| Q38166454 | Pharmacogenetics of the nuclear hormone receptors: the missing link between environment and drug effects? |
| Q34902476 | Plasma metabolomic profiles of breast cancer patients after short-term limonene intervention. |
| Q38039759 | Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response |
| Q36242891 | Puberty-specific promotion of mammary tumorigenesis by a high animal fat diet. |
| Q30395192 | Role of nuclear receptor SHP in metabolism and cancer |
| Q34465146 | Src-mediated cross-talk between farnesoid X and epidermal growth factor receptors inhibits human intestinal cell proliferation and tumorigenesis |
| Q42253372 | Synthetic FXR agonist GW4064 is a modulator of multiple G protein-coupled receptors |
| Q38815561 | The Intestinal Microbiome and Estrogen Receptor-Positive Female Breast Cancer |
| Q89587168 | The Microbiome as a Component of the Tumor Microenvironment |
| Q27339662 | The epoxygenases CYP2J2 activates the nuclear receptor PPARalpha in vitro and in vivo |
| Q40102152 | The farnesoid X receptor induces fetuin-B gene expression in human hepatocytes |
| Q33648565 | Three measurable and modifiable enteric microbial biotransformations relevant to cancer prevention and treatment |
| Q36494764 | Unifying mechanisms of action of the anticancer activities of triterpenoids and synthetic analogs |
| Q37635082 | Walnuts have potential for cancer prevention and treatment in mice |